Asenapine

證據等級: L5

預測適應症: 10 個

ASENAPINE: From Schizophrenia/Bipolar I Disorder to Major Affective Disorder

One-Sentence Summary

Asenapine is an atypical antipsychotic approved by the US FDA (2009) and EMA for the treatment of schizophrenia and acute manic or mixed episodes associated with bipolar I disorder, but is not currently registered in Taiwan. The TxGNN model predicts it may be effective for Major Affective Disorder, with 4 clinical trials and 19 publications supporting this direction — evidence highly consistent with its established global regulatory approvals. Among 10 TxGNN-predicted indications evaluated, major affective disorder is the only one reaching L1 evidence level and the sole actionable repurposing candidate in this analysis; the remaining 9 predictions (ranks 1–9) are all rated “Hold” (L5, no mechanistic link) and are not pursued further in this report.

Quick Overview

Item	Content
Original Indication	Schizophrenia; Bipolar I Disorder (manic/mixed episodes) — US/EU approved; not registered in Taiwan
Predicted New Indication	Major Affective Disorder
TxGNN Prediction Score	99.57%
Evidence Level	L1
Taiwan Market Status	✗ Not Marketed
Number of Licenses	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Asenapine is a multi-receptor antagonist with high binding affinity across the monoamine system. Although formal mechanism of action data was not retrieved in this evidence pack, its pharmacological profile is thoroughly characterized in the published literature: it acts as a high-affinity antagonist at dopamine D2/D3/D4 receptors (driving anti-manic effects), serotonin 5-HT2A/2C receptors (providing mood stabilization and reducing extrapyramidal side effects), histamine H1 receptors (producing sedation useful in acute mania), and α2-adrenergic receptors (enhancing norepinephrine and dopamine transmission). This broad receptor engagement addresses the dysregulated monoamine signaling that underlies both manic and mixed affective states.

Major affective disorder — encompassing bipolar I disorder and related severe mood disturbances — is precisely the therapeutic space for which asenapine was developed. D2/dopaminergic antagonism controls the excess dopaminergic tone that drives manic episodes, while 5-HT2A blockade complements mood stabilization and supports the transition to euthymia. The drug’s unique sublingual formulation avoids hepatic first-pass metabolism, resulting in rapid CNS absorption with a distinct pharmacokinetic profile compared to oral antipsychotics. This delivery advantage is clinically meaningful in acute agitated mania, where fast onset of action is essential.

The TxGNN prediction here is not speculative — it reflects a pharmacologically validated and globally approved application. Asenapine received FDA approval in August 2009 for adult bipolar I disorder (manic/mixed episodes) and expanded its pediatric indication (ages 10–17) in 2015. The European Medicines Agency (EMA) approved it under the brand name Sycrest® for the same indication. The model’s 99.57% confidence score accurately mirrors this real-world regulatory track record, and the clinical evidence base (3 completed Phase 3 RCTs, a meta-analysis of 4 RCTs, international treatment guidelines) firmly classifies this as an L1 repurposing candidate for the Taiwan market.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01244815	Phase 3	Completed	404	3-week double-blind, placebo-controlled RCT in pediatric patients aged 10–17 with bipolar I disorder (manic/mixed episodes); evaluated three fixed doses of asenapine vs. placebo; demonstrated statistically significant YMRS score reduction supporting US pediatric approval
NCT01349907	Phase 3	Completed	322	50-week open-label flexible-dose extension of NCT01244815; evaluated long-term safety and tolerability in pediatric bipolar I disorder; confirmed sustained improvement and acceptable safety over extended treatment
NCT00145470	Phase 3	Completed	326	12-week double-blind, placebo-controlled RCT in adults with bipolar I disorder (manic/mixed episodes) continuing lithium or valproate; asenapine as adjunct significantly improved manic symptoms vs. placebo; key pivotal trial supporting adult FDA approval
NCT02600741	N/A	Completed	296	12-month randomized open-label study of caregiver psycho-education and skills training for schizophrenia/schizoaffective disorder patients receiving antipsychotics; provides real-world psychiatric treatment context and outcome data relevant to affective disorder management

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23719049	2013	Meta-analysis	Int Clinical Psychopharmacology	Meta-analysis of 4 RCTs: asenapine significantly superior to placebo in YMRS and CGI-BP scores for acute bipolar mania; effect sizes clinically meaningful with favorable tolerability
28741044	2017	RCT	CNS Drugs	Open-label RCT comparing asenapine vs. olanzapine in borderline personality disorder with affective dysregulation; comparable efficacy on mood and impulsivity outcomes
37815563	2023	Systematic Review	JAMA	Comprehensive review of bipolar disorder diagnosis and treatment (affects ~8M US adults, ~40M worldwide); asenapine cited among recommended pharmacotherapies for manic episodes
20420486	2010	Pharmacology Review	Expert Rev Neurotherapeutics	Detailed characterization of asenapine’s receptor profile (5-HT2A > D2 affinity), effects on NMDA/AMPA receptors, and clinical efficacy in bipolar I disorder manic and mixed episodes
33460070	2020	Narrative Review	Acta Psychiatrica Scandinavica	Evidence-based clinical recommendations for bipolar mania management; asenapine included among antipsychotics with solid Phase 3 evidence for acute manic episodes
29170943	2018	Review	Paediatric Drugs	Review of asenapine in pediatric bipolar I disorder and schizophrenia; covers Phase 3 pediatric trial data, dosing recommendations (2.5–10 mg BID), and the regulatory basis for pediatric approval
20135021	2009	Review	Drugs of Today	Overview of asenapine maleate as a novel atypical antipsychotic at the time of initial FDA approval; describes pharmacodynamic profile and clinical differentiation from existing agents
35141987	2022	Case Report	Psychogeriatrics	Successful treatment of major depressive disorder with psychotic features using asenapine added to escitalopram in an elderly patient; demonstrates broader affective disorder utility beyond bipolar mania
28004626	2017	Review	CNS Spectrums	Review of pharmacotherapy for DSM-5 mixed features specifier; discusses asenapine’s role in treating mixed manic/hypomanic and depressive symptom combinations
33634761	2021	Case Report	CNS & Neurological Disorders Drug Targets	Case report of asenapine successfully treating catatonia in a COVID-19 patient with schizotypal personality disorder and psychotic depression in ICU; demonstrates clinical versatility in complex psychiatric presentations

Taiwan Market Information

Asenapine currently has no registered products in Taiwan (0 TFDA licenses). The table below summarizes the drug’s regulatory status in major markets outside Taiwan for reference:

Market	Product Name	Dosage Form	Approved Indication
US (FDA, 2009)	Saphris®	Sublingual tablet (2.5, 5, 10 mg)	Acute manic/mixed episodes of bipolar I disorder (adults and pediatric 10–17 years); schizophrenia (adults)
EU (EMA)	Sycrest®	Sublingual tablet	Acute manic episodes of bipolar I disorder (adults)

Safety Considerations

Formal safety data (TFDA package insert warnings, contraindications, drug interaction database records) were not retrieved in this evidence pack. Please refer to the official Saphris® US Prescribing Information or Sycrest® EU Summary of Product Characteristics for comprehensive safety information.

Based on published literature, the following safety signals are clinically important for asenapine:

Somnolence and sedation: H1 receptor antagonism produces significant sedation, especially at treatment initiation; relevant for outpatient management and driving safety
Metabolic effects: Weight gain and dyslipidemia reported, consistent with atypical antipsychotic class effects; fasting glucose and lipid monitoring recommended
QTc prolongation: Class-level cardiac risk; baseline ECG and monitoring in patients with cardiac risk factors advised
Oral hypoesthesia: Unique to sublingual formulation; transient numbness and tingling of the mouth/tongue occur in up to 5% of patients

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Asenapine has robust L1-level clinical evidence for major affective disorder (bipolar I disorder), anchored by multiple completed Phase 3 RCTs, a meta-analysis, international regulatory approvals (US FDA, EMA), and a mechanistically well-characterized pharmacological basis. The TxGNN prediction score of 99.57% accurately reflects this existing global evidence base. This is not speculative repurposing — the primary barrier to Taiwan market entry is regulatory and commercial, not scientific.

To proceed, the following is needed:

TFDA regulatory pathway: Determine feasibility of a new drug application (NDA) to TFDA for bipolar I disorder / major affective disorder; assess whether US/EU approval data packages meet TFDA bridging study requirements
Safety dossier completion: Retrieve TFDA-required package insert warnings, contraindications, and drug-drug interaction data from DrugBank API and official US/EU product labels
MOA documentation: Compile pharmacology data from DrugBank (DB06216) for formal regulatory submission and TFDA review
Taiwan epidemiology and unmet need: Estimate eligible bipolar I disorder patient population in Taiwan and assess positioning relative to currently reimbursed atypical antipsychotics (e.g., quetiapine, olanzapine, risperidone) under the National Health Insurance formulary
Commercial feasibility: Evaluate patent status, originator marketing authorization holder (Organon/formerly Allergan/AbbVie), and licensing or generic entry options for the Taiwan market
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.